Corbus Pharmaceuticals Holdings (id:5882 CRBP)
17.47 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 12:39:03 PM)
Exchange closed, opens in 1 day 20 hours
About Corbus Pharmaceuticals Holdings
Market Capitalization 204.13M
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Headquarters (address) |
500 River Ridge Drive Norwood 02062 MA United States |
| Phone | 617 963 0100 |
| Website | https://www.corbuspharma.com |
| Employees | 19 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CRBP |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.00 - 61.90 |
| Market Capitalization | 204.13M |
| P/E trailing | -1.69 |
| P/E forward | -3.20 |
| Price/Book | 1.36 |
| Beta | 2.56 |
| EPS | -4.71 |
| EPS United States (ID:6, base:3399) | 24.27 |